Ken Griffin Editas Medicine, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $11,187 - $19,668	3,300 Added 6.03%	58,000 $197,000
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $44,365 - $69,160	9,500 Added 21.02%	54,700 $255,000
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $805,638 - $1.27 Million	-114,600 Reduced 71.71%	45,200 $335,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $101,250 - $179,982	-16,200 Reduced 9.2%	159,800 $1.62 Million
Q3 2023 Nov 14, 2023	SELL	$6.92 - $9.31 $310,708 - $418,019	-44,900 Reduced 20.33%	176,000 $1.37 Million
Q2 2023 Aug 14, 2023	SELL	$6.36 - $11.47 $210,516 - $379,657	-33,100 Reduced 13.03%	220,900 $1.82 Million
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $404,928 - $664,128	-57,600 Reduced 18.49%	254,000 $1.84 Million
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $156,416 - $248,348	-18,800 Reduced 5.69%	311,600 $2.76 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $623,808 - $996,246	51,300 Added 18.38%	330,400 $4.04 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $152M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.